FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2089408076> ?p ?o ?g. }

• W2089408076 endingPage "183" @default.
• W2089408076 startingPage "173" @default.
• W2089408076 abstract "We investigated the potential of using novel zoledronic acid (ZOL)-hydroxyapatite (HA) nanoparticle based drug formulation in a rat model of postmenopausal osteoporosis. By a classical adsorption method, nanoparticles of HA loaded with ZOL (HNLZ) drug formulation with a size range of 100–130 nm were prepared. 56 female Wistar rats were ovariectomized (OVX) or sham-operated at 3 months of age. Twelve weeks post surgery, rats were randomized into seven groups and treated with various doses of HNLZ (100, 50 and 25 μg/kg, intravenous single dose), ZOL (100 μg/kg, intravenous single dose) and HA nanoparticle (100 μg/kg, intravenous single dose). Untreated OVX and sham OVX served as controls. After three months treatment period, we evaluated the mechanical properties of the lumbar vertebra and femoral mid-shaft. Femurs were also tested for trabecular microarchitecture. Sensitive biochemical markers of bone formation and bone resorption in serum were also determined. With respect to improvement in the mechanical strength of the lumbar spine and the femoral mid-shaft, the therapy with HNLZ drug formulation was more effective than ZOL therapy in OVX rats. Moreover, HNLZ drug therapy preserved the trabecular microarchitecture better than ZOL therapy in OVX rats. Furthermore, the HNLZ drug formulation corrected increase in serum levels of bone-specific alkaline phosphatase, procollagen type I N-terminal propeptide, osteocalcin, tartrate-resistant acid phosphatase 5b and C-telopeptide of type 1 collagen better than ZOL therapy in OVX rats. The results strongly suggest that HNLZ novel drug formulation appears to be more effective approach for treating severe osteoporosis in humans." @default.
• W2089408076 created "2016-06-24" @default.
• W2089408076 creator A5027082048 @default.
• W2089408076 creator A5049934921 @default.
• W2089408076 creator A5078256024 @default.
• W2089408076 date "2015-01-01" @default.
• W2089408076 modified "2023-10-16" @default.
• W2089408076 title "Development, in vitro and in vivo characterization of zoledronic acid functionalized hydroxyapatite nanoparticle based formulation for treatment of osteoporosis in animal model" @default.
• W2089408076 cites W1971280064 @default.
• W2089408076 cites W1972940389 @default.
• W2089408076 cites W1978055205 @default.
• W2089408076 cites W1980154423 @default.
• W2089408076 cites W1990817608 @default.
• W2089408076 cites W1991610798 @default.
• W2089408076 cites W1993035292 @default.
• W2089408076 cites W2003558042 @default.
• W2089408076 cites W2003692790 @default.
• W2089408076 cites W2003832763 @default.
• W2089408076 cites W2004980416 @default.
• W2089408076 cites W2005785120 @default.
• W2089408076 cites W2013819035 @default.
• W2089408076 cites W2022225856 @default.
• W2089408076 cites W2022641082 @default.
• W2089408076 cites W2037752243 @default.
• W2089408076 cites W2043280737 @default.
• W2089408076 cites W2045408633 @default.
• W2089408076 cites W2046077223 @default.
• W2089408076 cites W2054138009 @default.
• W2089408076 cites W2055802170 @default.
• W2089408076 cites W2059791081 @default.
• W2089408076 cites W2079830503 @default.
• W2089408076 cites W2082199998 @default.
• W2089408076 cites W2103545729 @default.
• W2089408076 cites W2105452900 @default.
• W2089408076 cites W2107454545 @default.
• W2089408076 cites W2110396808 @default.
• W2089408076 cites W2136583590 @default.
• W2089408076 cites W2143228190 @default.
• W2089408076 cites W2158867101 @default.
• W2089408076 cites W2338598701 @default.
• W2089408076 doi "https://doi.org/10.1016/j.ejps.2014.10.015" @default.
• W2089408076 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25444840" @default.
• W2089408076 hasPublicationYear "2015" @default.
• W2089408076 type Work @default.
• W2089408076 sameAs 2089408076 @default.
• W2089408076 citedByCount "58" @default.
• W2089408076 countsByYear W20894080762016 @default.
• W2089408076 countsByYear W20894080762017 @default.
• W2089408076 countsByYear W20894080762018 @default.
• W2089408076 countsByYear W20894080762019 @default.
• W2089408076 countsByYear W20894080762020 @default.
• W2089408076 countsByYear W20894080762021 @default.
• W2089408076 countsByYear W20894080762022 @default.
• W2089408076 countsByYear W20894080762023 @default.
• W2089408076 crossrefType "journal-article" @default.
• W2089408076 hasAuthorship W2089408076A5027082048 @default.
• W2089408076 hasAuthorship W2089408076A5049934921 @default.
• W2089408076 hasAuthorship W2089408076A5078256024 @default.
• W2089408076 hasConcept C125870589 @default.
• W2089408076 hasConcept C126322002 @default.
• W2089408076 hasConcept C126894567 @default.
• W2089408076 hasConcept C131075544 @default.
• W2089408076 hasConcept C134018914 @default.
• W2089408076 hasConcept C150903083 @default.
• W2089408076 hasConcept C160160445 @default.
• W2089408076 hasConcept C181199279 @default.
• W2089408076 hasConcept C185592680 @default.
• W2089408076 hasConcept C207001950 @default.
• W2089408076 hasConcept C2776326535 @default.
• W2089408076 hasConcept C2776541429 @default.
• W2089408076 hasConcept C2777164284 @default.
• W2089408076 hasConcept C55493867 @default.
• W2089408076 hasConcept C673006 @default.
• W2089408076 hasConcept C71924100 @default.
• W2089408076 hasConcept C8264082 @default.
• W2089408076 hasConcept C86803240 @default.
• W2089408076 hasConcept C98274493 @default.
• W2089408076 hasConceptScore W2089408076C125870589 @default.
• W2089408076 hasConceptScore W2089408076C126322002 @default.
• W2089408076 hasConceptScore W2089408076C126894567 @default.
• W2089408076 hasConceptScore W2089408076C131075544 @default.
• W2089408076 hasConceptScore W2089408076C134018914 @default.
• W2089408076 hasConceptScore W2089408076C150903083 @default.
• W2089408076 hasConceptScore W2089408076C160160445 @default.
• W2089408076 hasConceptScore W2089408076C181199279 @default.
• W2089408076 hasConceptScore W2089408076C185592680 @default.
• W2089408076 hasConceptScore W2089408076C207001950 @default.
• W2089408076 hasConceptScore W2089408076C2776326535 @default.
• W2089408076 hasConceptScore W2089408076C2776541429 @default.
• W2089408076 hasConceptScore W2089408076C2777164284 @default.
• W2089408076 hasConceptScore W2089408076C55493867 @default.
• W2089408076 hasConceptScore W2089408076C673006 @default.
• W2089408076 hasConceptScore W2089408076C71924100 @default.
• W2089408076 hasConceptScore W2089408076C8264082 @default.
• W2089408076 hasConceptScore W2089408076C86803240 @default.
• W2089408076 hasConceptScore W2089408076C98274493 @default.
• W2089408076 hasLocation W20894080761 @default.
• W2089408076 hasLocation W20894080762 @default.

• next